{{Chembox|ImageFile=Triptolide.svg|ImageSize=200px|Section1={{Chembox Identifiers
| CASNo = 38748-32-2
|  PubChem = 107985
|  ChemSpiderID = 97099
|  SMILES = CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C
|  StdInChI = 1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
|  StdInChIKey = DFBIRQPKNDILPW-CIVMWXNOSA-N
|  ChEBI = 9747
|  KEGG = C09204}}|Section2={{Chembox Properties
| C=20 | H=24 | O=6
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = 0.017 mg/mL<ref>{{cite journal|last1=Patil|first1=Satish|last2=Lis|first2=Lev G.|last3=Schumacher|first3=Robert J.|last4=Norris|first4=Beverly J.|last5=Morgan|first5=Monique L.|last6=Cuellar|first6=Rebecca A. D.|last7=Blazar|first7=Bruce R.|last8=Suryanarayanan|first8=Raj|last9=Gurvich|first9=Vadim J.|last10=Georg|first10=Gunda I.|title=Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts|journal=Journal of Medicinal Chemistry|date=10 December 2015|volume=58|issue=23|pages=9334–9344|doi=10.1021/acs.jmedchem.5b01329|pmid=26596892|pmc=4678411}}</ref>
}}|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = }}}}

'''雷公藤内酯'''是一个二萜类[[环氧化合物|环氧化物]]，它由[[雷公藤|雷公藤]]（学名：''Tripterygium wilfordii''）产生。 它在体外实验和体内实验中对[[模式生物|小鼠模型]]的[[多囊性腎病變|多囊肾病]]<ref>{{Cite journal|title=Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease|url=http://www.pnas.org/content/104/11/4389.abstract|last=Leuenroth|first=Stephanie|journal=PNAS|accessdate=18 October 2012|issue=11|doi=10.1073/pnas.0700499104|year=2007|volume=104|pages=4389–4394|pmc=1838612|pmid=17360534}}</ref>和[[胰腺癌|胰腺癌]]具有抗癌作用，但是其物理性质<ref name="Chugh">{{Cite journal|title=A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer|url=http://stm.sciencemag.org/content/4/156/156ra139.abstract|last=Chugh|first=Rohit|journal=Science Translational Medicine|accessdate=18 October 2012|issue=156|doi=10.1126/scitranslmed.3004334|year=2012|volume=4|pages=156ra139|pmc=3656604|pmid=23076356}}</ref>和严重的毒性<ref name="Liu2011">{{Cite journal|title=Triptolide and its expanding multiple pharmacological functions|author=Liu Q.|journal=International Immunopharmacology|issue=3|doi=10.1016/j.intimp.2011.01.012|year=2011|volume=11|pages=377–383|pmid=21255694}}</ref>限制了它的治疗潜力。

因此，合成的水溶性[[前体药物|前体药物]]Minnelide正在进行临床上的研究。<ref>{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT01927965|title=Study of Minnelide in Patients With Advanced GI Tumors|accessdate=6 October 2016}}</ref>

== 作用机理 ==
几个可能的的雷公藤内脂的目标蛋白质已经被报告出来，包括[[polycystin-2|polycystin-2]]、<ref>S. J. Leuenroth, D. Okuhara, J. D. Shotwell, G. S. Markowitz, Z. Yu, S. Somlo, C. M. Crews, Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. ''Proc Natl Acad Sci U S A'' 2007, 104, 4389-4394;</ref>[[ADAM10|ADAM10]]、<ref>R. Soundararajan, R. Sayat, G. S. Robertson, P. A. Marignani,Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. ''Cancer Biol Ther'' 2009, 8, 2054-2062;</ref>[[DCTPP1|DCTPP1]]、<ref>T. W. Corson, H. Cavga, N. Aberle, C. M. Crews, Triptolide directly inhibits dCTP pyrophosphatase.  ''Chembiochem'' 2011, 12, 1767-1773;</ref>[[TAB1|TAB1]]、<ref>Y. Lu, Y. Zhang, L. Li, X. Feng, S. Ding, W.Zheng, J. Li, P. Shen,TAB1: A Target of Triptolide in Macrophages. ''Chem. Biol.'' 2014, 21, 246 – 256.</ref>和[[XPB|XPB]]。<ref>D. V. Titov, B. Gilman, Q. L.He, S. Bhat,W. K. Low, Y. Dang,M.Smeaton, A. L. Demain, P. S. Miller, J. F. Kugel, J. A. Goodrich,J. O. Liu, XPB, a subunit of TFIIH, is a target of the natural product triptolide.  ''Nat. Chem. Biol.'' 2011, 7, 182 – 188.</ref>多雷公藤抗性基因突变中存在XPB(ERCC3)及其协同的蛋白质 [[GTF2H4|GTF2H4]]。<ref name="feng2014">Y. Smurnyy, M. Cai, H. Wu, E. McWhinnie, J. A. Tallarico, Y.Yang, Y. Feng, DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells.  ''Nat. Chem. Biol''. 2014, 10, 623 – 625</ref>然而，没有雷公藤抗性基因突变也在 [[polycystin-2|polycystin-2]]、[[ADAM10|ADAM10]]、[[DCTPP1|DCTPP1]]和[[TAB1|TAB1]]中被发现。 [[XPB|XPB]]的[[半胱氨酸|Cys]]342被认定为经由雷公藤内酯的12,13-环氧化物基团进行共价修饰的残基，而XPB-C342T突变呈现的T7115[[细胞系|细胞系]]几乎完全耐受雷公藤内酯。<ref name="Liu2015">Q. L. He, D. V. Titov, J. Li, M. Tan, Z. Ye, Y. Zhao, D. Romo, and J. O. Liu. Covalent Modification of a Cysteine Residue in the XPB Subunit of the General Transcription Factor TFIIH Through Single Epoxide Cleavage of the Transcription Inhibitor Triptolide. ''Angew. Chem. Int. Ed.'' 2015, 54, 1859 –1863</ref>由C342T突变导致的耐受水平是之前确定的大多数雷公藤内酯耐受突变的约100倍。 综上所述，这些结果说明[[XPB|XPB]]是雷公藤内酯影响细胞增殖活动的目标。

== 水溶性的前体药物 ==
Minnelide是一种由人工合成，具有更好的水溶性的雷公藤内酯类似物，它可以在体内转化为雷公藤内酯。<ref name="GN-min-2012">[http://www.genengnews.com/gen-news-highlights/thunder-god-vine-drug-zaps-pancreatic-cancer/81247498/ Thunder God Vine Drug Zaps Pancreatic Cancer. GenEng. 2012]</ref>在临床前期的小鼠模型胰腺癌中，他的表现比[[吉西他滨|吉西他滨]]更有效。临床一期研究计划于2012年展开。

糖化雷公藤甲素是一种葡萄糖与雷公藤内酯合成的的化合物，具有更好的溶解性以及更低的毒性。它在体外实验中并没有抑制[[XPB|XPB]]的活性，但在体内实验中被发现有抗癌活性，这可能是雷公藤内酯在癌细胞内持续逐步被释放出来的缘故。<ref>{{Cite journal|title=Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation|last=He|first=Qing-Li|last2=Minn|first2=Il|journal=Angewandte Chemie|issue=39|doi=10.1002/ange.201606121|year=2016|volume=128|pages=12214|last3=Wang|first3=Qiaoling|last4=Xu|first4=Peng|last5=Head|first5=Sarah A|last6=Datan|first6=Emmanuel|last7=Yu|first7=Biao|last8=Pomper|first8=Martin G|last9=Liu|first9=Jun O}}</ref>

== 参考文献 ==
{{reflist|2}}
[[Category:环氧化合物|Category:环氧化合物]]